Furthermore, in vivo studies on other types of cancer, such as acute myeloid leukemia [55], bladder cancer [121], and breast cancer [122] have shown that the inhibition of SEMA4D has therapeutic potential. This evidence concerns the gene SEMA4D and urinary bladder carcinoma.